- Home
- BOBS vs RAPP Comparison
BOBS vs RAPP Comparison
Compare BOBS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOBS | RAPP |
|---|---|---|
| Founded | 1991 | 2022 |
| Country | United States | United States |
| Employees | 5950 | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | BOBS | RAPP |
|---|---|---|
| Price | $16.20 | $42.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $23.73 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.0M | 436.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.58 | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.74 | $13.64 |
| 52 Week High | $23.11 | $43.76 |
Technical Indicators
Market Signals| Indicator | BOBS | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 58.90 |
| Support Level | $14.33 | $33.54 |
| Resistance Level | $16.70 | $43.70 |
| Average True Range (ATR) | 0.94 | 2.78 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 63.40 | 66.19 |
Price Performance
Historical ComparisonAbout BOBS Bob's Discount Furniture Inc. Common Stock
Bobs Discount Furniture Inc operates as a furniture retailer offering a wide variety of merchandise assortments across several categories, including upholstery, case goods, bedding, and other. The company generates the majority of its revenue from the sale of its products through its retail stores.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.